BRPI0711256A2 - composições anticancerìgenas e método de tratamento de cáncer - Google Patents

composições anticancerìgenas e método de tratamento de cáncer Download PDF

Info

Publication number
BRPI0711256A2
BRPI0711256A2 BRPI0711256-4A BRPI0711256A BRPI0711256A2 BR PI0711256 A2 BRPI0711256 A2 BR PI0711256A2 BR PI0711256 A BRPI0711256 A BR PI0711256A BR PI0711256 A2 BRPI0711256 A2 BR PI0711256A2
Authority
BR
Brazil
Prior art keywords
cancer treatment
taxane
anticancer
produce
compositions
Prior art date
Application number
BRPI0711256-4A
Other languages
English (en)
Inventor
Richard D Olson
Gerald M Walsh
Original Assignee
Gem Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gem Pharmaceuticals Llc filed Critical Gem Pharmaceuticals Llc
Publication of BRPI0711256A2 publication Critical patent/BRPI0711256A2/pt
Publication of BRPI0711256B1 publication Critical patent/BRPI0711256B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIçõES ANTICANCERìGENAS E MéTODO DE TRATAMENTO DE CáNCER. Uma 13-deoxi antraciclina e uma taxana podem ser administradas a um paciente simultanea, separada, sequencial ou consecutivamente para produzir um efeito anticâncer terapêutico com toxicidade e perfil de efeito colateral reduzido, comparado com a administração de quantidades equiefetivas de um ou outro composto apenas. Também é proporcionada uma composição ou uma preparação de 13-deoxi antraciclinas e uma taxana para produzir um potente efeito terapêutico anticancerígeno.
BRPI0711256-4A 2006-04-21 2007-04-23 Composições anticancerígenas BRPI0711256B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/408,000 US7776832B2 (en) 2006-04-21 2006-04-21 Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
US11/408,000 2006-04-21
PCT/US2007/067225 WO2007124489A2 (en) 2006-04-21 2007-04-23 Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines

Publications (2)

Publication Number Publication Date
BRPI0711256A2 true BRPI0711256A2 (pt) 2011-08-30
BRPI0711256B1 BRPI0711256B1 (pt) 2025-01-21

Family

ID=

Also Published As

Publication number Publication date
PT2010191T (pt) 2021-01-04
WO2007124489A3 (en) 2008-10-23
RU2421224C2 (ru) 2011-06-20
US20070249547A1 (en) 2007-10-25
JP2009534426A (ja) 2009-09-24
MX2008013546A (es) 2009-01-20
EP2010191B1 (en) 2020-10-07
RU2008141682A (ru) 2010-05-27
DK2010191T3 (da) 2020-12-14
ES2840977T3 (es) 2021-07-07
JP5011377B2 (ja) 2012-08-29
KR101514336B1 (ko) 2015-04-22
UA90597C2 (ru) 2010-05-11
CO6190526A2 (es) 2010-08-19
US7776832B2 (en) 2010-08-17
NZ572012A (en) 2011-09-30
KR20090010981A (ko) 2009-01-30
WO2007124489A2 (en) 2007-11-01
CN101426509A (zh) 2009-05-06
CA2649753C (en) 2011-09-27
PL2010191T3 (pl) 2021-05-04
US20100311679A1 (en) 2010-12-09
AU2007240264A1 (en) 2007-11-01
US8158591B2 (en) 2012-04-17
ZA200808892B (en) 2009-10-28
EP2010191A4 (en) 2010-05-26
IL194707A (en) 2015-10-29
AU2007240264B2 (en) 2012-11-01
EP2010191A2 (en) 2009-01-07
CA2649753A1 (en) 2007-11-01
IL194707A0 (en) 2009-08-03
MY148571A (en) 2013-04-30

Similar Documents

Publication Publication Date Title
MY148571A (en) Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
NZ621433A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EA200901155A1 (ru) Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
HK1200716A1 (zh) 使用胞苷類似物的口服製劑治療癌症的方法
CY1111433T1 (el) Φαρμακευτικο τυποποιημενο παρασκευασμα δεσιταβινης
EP3501546A3 (de) Cystein-wirkstoff konjugate und ihre verwendung
BR112014014181A2 (pt) combinação de ozogamicina inotuzumab e torisel para o tratamento de câncer
SI2268292T1 (en) Method and compositions for the treatment of cancer
MX2014002555A (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
NZ588913A (en) Liver cancer drug
PE20081799A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
BR112012002265B8 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
EA200870421A1 (ru) Димеры производных артемизинина, их получение и их применение в терапии
TN2012000493A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
WO2014160216A3 (en) Dual targeting anticancer agents
MX2025009943A (es) Derivado de camptotecina, su conjugado, su metodo de preparacion y su uso medico
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/04/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2824 DE 18-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.